Raymond R. Schleef
Scripps Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Raymond R. Schleef.
Journal of Clinical Investigation | 1986
Michael P. Bevilacqua; Raymond R. Schleef; Michael A. Gimbrone; David J. Loskutoff
We examined the effects of human interleukin 1 (IL-1) on the production of fibrinolytic components by cultured human vascular endothelium. Conditioned media collected from IL-1-treated (5 U/ml, 24 h) monolayers exhibited decreased tissue-type plasminogen activator (tPA) activity and increased plasminogen activator inhibitor (PAI) activity, as assessed by fibrin and reverse fibrin-autography. Quantitative immunological assays revealed a 35% decrease in tPA antigen and a 360% increase in active PAI antigen, after incubation for 24 h with 0.6 U/ml IL-1. Maximal effects (approximately 50% decrease in tPA antigen; 400-800% increase in active PAI antigen) were observed with 2.5-5 U/ml IL-1. Changes in tPA and PAI reached a maximum at approximately 24 h and persisted for greater than 48 h. IL-1 induction of endothelial procoagulant activity was more rapid and transient, peaking by 6 h and subsiding by 24 h. Natural monocyte-derived IL-1 and two species of recombinant IL-1 had comparable effects. Heat and polymyxin-B treatments differentiated IL-1 actions from those of endotoxin, which promoted similar endothelial alterations. IL-1 effects on endothelial procoagulant and fibrinolytic activities may contribute to the generation and maintenance of fibrin in pathophysiological settings in vivo.
Mechanisms of Development | 1990
D. Seiffert; Jun Mimuro; Raymond R. Schleef; David J. Loskutoff
Regulation of plasminogen activation is a key process in controlling proteolytic events in the extracellular matrix (ECM) and this regulation is achieved through the action of specific plasminogen activator (PA) inhibitors (PAIs). Type I PAI (PAI-1) is the physiological inhibitor both of urinary-type PA (u-PA) and tissue-type PA (t-PA) (Loskutoff et al., 1989) and is a major component of the ECM of cultured cells. This inhibitor may protect ECM constituents against cellular proteases and thus influence the cell migration and tissue destruction that occurs during development, inflammation and tumor metastasis. In this review, we discuss the properties of PAI-1 and the evidence that the binding of PAI-1 to ECM is mediated by serum-derived vitronectin (Vn).
Pathophysiology of Haemostasis and Thrombosis | 1988
Raymond R. Schleef; David J. Loskutoff
The regulation of the fibrinolytic system is of critical importance during hemostasis, wound repair, neoplasia, inflammation, and a variety of other biologic processes. This control is achieved in a l
Journal of Biological Chemistry | 1988
Raymond R. Schleef; Michael P. Bevilacqua; M Sawdey; Michael A. Gimbrone; David J. Loskutoff
Journal of Cell Biology | 1990
Raymond R. Schleef; Thomas J. Podor; Eileen Dunne; Jun Mimuro; David J. Loskutoff
Journal of Cellular Physiology | 1988
Raymond R. Schleef; Nancy Wagner; David J. Loskutoff
Thrombosis and Haemostasis | 1986
David J. Loskutoff; Karen Roegner; Larry A. Erickson; Raymond R. Schleef; Anna Huttenlocher; Patrick L. Coleman; Thomas D. Gelehrter
Journal of Cell Biology | 1991
Raymond R. Schleef; David J. Loskutoff; Thomas J. Podor
Methods in Enzymology | 1988
David J. Loskutoff; Raymond R. Schleef
Archive | 1984
David J. Loskutoff; Raymond R. Schleef